Appointments: Basliea, BenevolentAI, OMEICOS, Recursion, Takeda UK And Bone Therapeutics Announce New Hires
Executive Summary
New appointments have been announced this week by Basilea, BenevolentAI, OMEICOS Therapeutics, Pharnext, Recursion Pharmaceuticals, Sonde Health, Takeda UK, Bone Therapeutics and Glythera.
You may also be interested in...
With First IND, Recursion Readies Its AI, Experimental Biology Approach For The Clinic
Emerging Company Profile: With an early focus on rare, monogenic diseases, Recursion believes its platform combining artificial intelligence and experimental biology can be applied to any disease that can be modeled on a cellular level.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements
Recent moves in the industry include C-suite shuffle at Brainstorm Cell Therapeutics and new CFOs at Faron Pharmaceuticals and Foghorn Therapeutics, among others.